Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Gilead Sciences, Inc. (NASDAQ:GILD) has been given a consensus rating of “Moderate Buy” by the twenty-nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-five have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $156.9259.

GILD has been the subject of a number of recent research reports. Argus boosted their price target on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. TD Cowen lifted their price objective on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Scotiabank lifted their price objective on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $160.00 price objective on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. The trade was a 1.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 53,000 shares of company stock valued at $7,075,670 in the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Avidity Partners Management LP purchased a new position in Gilead Sciences in the 1st quarter worth approximately $2,787,000. Allen Capital Group LLC lifted its holdings in Gilead Sciences by 4.9% in the 1st quarter. Allen Capital Group LLC now owns 2,400 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 112 shares in the last quarter. Axiom Investment Management LLC purchased a new position in Gilead Sciences in the 1st quarter worth approximately $677,000. J. Derek Lewis & Associates Inc. lifted its holdings in Gilead Sciences by 7.1% in the 1st quarter. J. Derek Lewis & Associates Inc. now owns 3,020 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 200 shares in the last quarter. Finally, Groupe la Francaise lifted its holdings in Gilead Sciences by 12.2% in the 1st quarter. Groupe la Francaise now owns 37,915 shares of the biopharmaceutical company’s stock worth $5,284,000 after purchasing an additional 4,118 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 1.3%

Shares of Gilead Sciences stock opened at $134.43 on Friday. The company has a market cap of $166.90 billion, a price-to-earnings ratio of 18.31 and a beta of 0.31. The company’s 50 day moving average is $135.30 and its 200 day moving average is $134.09. Gilead Sciences has a twelve month low of $104.46 and a twelve month high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts anticipate that Gilead Sciences will post -0.79 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.